Krystal Biotech (KRYS) Current Assets (2016 - 2026)

Krystal Biotech has disclosed Current Assets across 11 years of filings, most recently posting $1.0 billion for Q1 2026.

• Current Assets for Q1 2026 came in at $1.0 billion, up 32.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 32.99% YoY), and the FY2025 annual result was $1.0 billion, up 38.08% from the prior year.
• Current Assets came in at $1.0 billion for Q1 2026 at Krystal Biotech, roughly flat from $1.0 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.0 billion in Q4 2025 to a low of $355.4 million in Q1 2023.
• The 5-year median for Current Assets is $602.2 million (2024), against an average of $645.6 million.
• Across the five-year window, Current Assets slipped 18.85% in 2023 and soared 69.44% in 2024, its largest moves.
• Krystal Biotech's Current Assets stood at $383.8 million in 2022, then jumped by 53.19% to $587.9 million in 2023, then gained by 26.22% to $742.0 million in 2024, then surged by 38.08% to $1.0 billion in 2025, then retreated by 0.47% to $1.0 billion in 2026.
• The last three Current Assets figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $925.6 million (Q3 2025), per Business Quant data.